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Abstract
Background Cancer cachexia is a condition often seen at diagnosis, throughout anti-cancer treatments and in end-stage
nonsmall- cell lung cancer patients.
Methods and results Participants with late-stage non-small-cell lung cancer and cachexia (defined as ≥5% weight loss within
12 months) were randomly assigned 1:2 to 2.09 g of eicosapentaenoic acid (EPA) and 300 mg of cyclo-oxygenase-2 inhibitor
celecoxib orally once daily vs. same dosing of EPA, celecoxib, plus two sessions per week of progressive resistance training and
20 g of oral essential amino acids high in leucine in a split dose over 3 days, after each session. Primary endpoint was the ac-
ceptability of the earlier multi-targeted approach. Main secondary endpoints included change in body weight and fat-free
mass, by bioelectric impedance analysis and total quadriceps muscle volume by magnetic resonance imaging over 20 weeks.
Sixty-nine patients were screened resulting in 20 patients being enrolled. Acceptability scored high, with 4.5/5 (Arm A) and 5/5
(Arm B) for EPA and 5/5 for celecoxib within both arms and 4.8/5 for progressive resistance training sessions and 4.5/5 for
essential amino acids within Arm B, all at Week 20. Results showed a net gain in bioelectric impedance analysis fat-free mass
of +1.3 kg, n = 2 (Arm A), compared with +0.7 kg, n = 7 (Arm B) at Week 12, and —1.5 kg, n = 2 (Arm A), compared with —1.7
kg, n = 4 (Arm B) at Week 20. Trends in efficacy in terms of improvement and/or stability in cachexia markers were seen within
magnetic resonance imaging muscle volume, albumin, and C-reactive protein levels within both arms. There were no exercise-
related adverse events, with one possible related adverse event of asymptomatic atrial fibrillation in one participant within
Arm A.
Conclusions Non-small-cell lung cancer cachectic patients are willing to be enrolled onto a multi-targeted treatment regimen
and may benefit from cachexia symptom management even during the late/refractory stage.
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Introduction
The most widely used definition for cancer cachexia found is
‘a multifactorial syndrome characterized by an ongoing loss
of skeletal muscle mass (with or without loss of fat mass) that
cannot be fully reversed by conventional nutritional support
and leads to progressive functional impairment’.1 Over the
last few decades, a number of pharmacological agents and
methods of support have been investigated to address the
primary areas of cancer cachexia,2,3 either by monotherapy
or by combinations of agents.4–6 Recent publications have
shown progress in a number of areas including the ghrelin re-
ceptor agonist anamorelin, which possesses both anabolic
and appetite-stimulating properties, as per ROMANA 1, 2,
and 3 studies,7,8 the novel non-selective beta-blocker with
central 5-HT1a and partial β2 receptor agonist espindolol,
which possesses both anabolic and anti-catabolic properties,
as per ACT-ONE study,9 and the anabolic properties of
testosterone.10
During this time, there has been a change in the
consideration of cachexia from a ‘very late change’ and
inescapable event to ‘an early phenomenon’ with signs of
cachexia present upon primary cancer diagnosis even if
weight loss has not yet occurred. This has led to the recent
shift in developing effective treatments aimed at preventing
rather than reversing the symptoms, as seen in the earlier
studies.7–10
This is in contrast to results of earlier clinical cachexia stud-
ies where anti-cancer treatment was not permitted and re-
cruited from end-stage cancer populations, which showed
efficacy with significant improvements in cachexia endpoints
including bone-free arm muscle mass and body weight,11
physical functioning and weight (gastrointestinal group),12
and increase in body weight and handgrip, with decreased
C-reactive protein (CRP) levels,13 all in placebo-controlled,
randomized studies in late-stage refractory cancer cachexia.
Completion rates have also been shown to be similar within
these earlier studies, ranging from 43% (n = 50)11 to 60%
(n = 200)14 at 8 weeks.
Current published literature in palliative care includes an
open-label study of twice weekly exercise in palliative pa-
tients for 6 weeks. Results showed efficacy and safety within
this end-stage cancer population.15 A recent systematic re-
view and meta-analysis of 66 high-quality exercise in cancer
studies supported emerging evidence and the many benefits
of exercise at various time points within the cancer journey.16
Views of palliative care patients and their relatives regarding
participating within a palliative care research study have re-
cently being reviewed.17 Eight studies were identified, with
common themes including a desire to retain autonomy, altru-
ism, and the potential for personal gain by participating in a
research study, and patients were generally happy to partici-
pate and did want research studies to be offered and
discussed.17
Recent knowledge gained around the loss of skeletal mus-
cle mass being the main component of cancer cachexia has
led to the need to measure and quantify skeletal muscle, in
terms of stabilization or increase/loss in both skeletal muscle
mass/volume and strength.2 Muscle strength and function
can be inferred from the analysis of muscle volume, and mea-
suring this over time is important in assessing changes during
ageing, training, and disease processes. The current ‘gold
standard’ of measuring muscle volume involves utilizing con-
tiguous transverse magnetic resonance imaging (MRI)
scans.18 Additional benefits of MRI analysis include the anal-
ysis of both muscle volume and anatomical cross-sectional
area, along with morphological features and distribution,
and can characterize the loss of muscle quality, for example,
intramuscular fat infiltration, fibrous connective tissue, and
oedema.19 This is becoming important as loss of mobility
has been shown to be related to muscle strength and in-
creased muscle lipid content, which can be quantified by both
MRI and magnetic resonance spectroscopy.19
In theory, an effective treatment for cancer cachexia may
require a multi-targeted approach. The combination of the
anti-cachectic agent eicosapentaenoic acid (EPA) and the cy-
clo-oxygenase-2 (COX-2) inhibitor celecoxib has been previ-
ously tested in a small study in non-small-cell lung cancer
(NSCLC) patients with some benefit.13 Similarly, the use of
progressive resistance training (PRT) and/or the oral ingestion
of essential amino acids (EAA) has been reported to provide a
potent anabolic stimulus on skeletal muscle and appears ac-
ceptable in older adults and other cancer groups.20,21
The study combination was chosen to target and decrease
the pro-inflammatory cytokines by using a COX-2 inhibitor
(celecoxib) and EPA and increase muscle anabolism with
PRT and EAA high in leucine post-exercise, with the overall
goal of stabilizing the effect of muscle catabolism/anabolism
to a potential net gain in overall muscle mass. It was decided
to improve body composition analysis within this study in
terms of utilizing 3T MRI scanner data and to use the analysis
of muscle volume to represent muscle strength and func-
tion.18 This analysis was to be combined with a formal assess-
ment of leg strength testing, which has been utilized within
exercise studies within various cancer populations.22,23
Materials and methods
Study design
Auckland’s Cancer Cachexia evaluating Resistance Training
(ACCeRT) study is a single-centre, open-label, prospective,
randomized controlled feasibility study. All participants
provided written informed consent. The study protocol was
approved by Northern Y Ethics Committee, Hamilton, New
Zealand (NTY/11/06/064), and complied with the
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International Ethical Guidelines for Biomedical Research In-
volving Human Subjects, Good Clinical Practice Guidelines,
and the Declaration of Helsinki. Study protocol has been pub-
lished24 and registered with Australian New Zealand Clinical
Trials Registry. Eligible patients were at least 18 years of
age; had histologically confirmed NSCLC; had cachexia as
per Evans et al.25 (defined as involuntary weight loss of ≥5%
within the previous 12 months or body mass index <20 kg/
m2); and had three of the following: decreased muscle
strength, fatigue, anorexia, low fat-free mass (FFM), and ab-
normal biochemistry [CRP >5 mg/L, interleukin (IL)-
6 > 4 pg/mL, haemoglobin <12 g/dL, and hypoalbuminaemia
<3.2 g/dL]. Eligible participants had been assessed, and no
further treatment was available to them indicating end-stage
refractory cachexia. Participants were required to have a life
expectancy of at least 4 months. Exclusion criteria included
the use of appetite stimulants (medroxyprogesterone ace-
tate, megestrol acetate, 4 mg o.d. of dexamethasone, or
30 mg o.d. of prednisolone), pleural effusion that causes
greater than or equal to CTC grade 2 dyspnoea, or an abnor-
mal baseline 12-lead electrocardiogram.
Randomization and masking
Participants were randomly assigned (1:2) to Arm A; EPA and
COX-2 inhibitor (celecoxib) or Arm B; and EPA, COX-2 inhibitor
(celecoxib), PRT, and EAA by a randomization table created by
computerized sequence generation. Enclosed treatment
assignments were serially numbered in opaque, sealed
envelopes and opened sequentially after the participant’s
name and other details had been written on the appropriate
envelope.26 The ACCeRT study was open label, and all
participants were aware of the allocated treatments.
Research staff assessing MRI analysis were masked to the
participants’ assigned intervention group throughout the
analysis.
Procedures
All participants received orally 5.5 mL (2.09 g) of EPA plus
300 mg celecoxib o.d. mane, with participants allocated to
Arm B receiving two PRT sessions per week (Tuesdays and Fri-
days), followed by 20 g of EAA high in leucine in split dose
over the following 3 days. Study period of 20 weeks, with
all participants having the opportunity to continue and/or re-
ceive study medication/training sessions under compassion-
ate use. These results will be published separately.
Participants could withdraw at any time or at the discretion
of the investigator because of further progression of their dis-
ease. Dose reductions or interruptions of EPA, celecoxib, PRT,
and EAA were permitted.
Acceptability was assessed by the analysis of a patient-
rated Likert-scored questionnaire asking 10 questions on
the acceptability of the earlier multi-targeted approach
(Supporting Information, Figure S1). Both groups were asked
five core questions around the acceptability/palatability of
taking the EPA and celecoxib daily and if they wish to con-
tinue with this medication. Participants allocated to Arm A
were asked one further question to determine if they would
like to commence the PRT sessions and EAA. Participants allo-
cated to Arm B were asked further four questions on the ac-
ceptability/palatability of participating in the PRT sessions
and taking the EAA and if they wish to continue with this
component of the study. Likert scores had a range of 1 for
‘strongly disagree’ to 5 for ‘strongly agree’; therefore, the
higher the score representing, the higher the acceptability
of the study medication and/or programme. Body composi-
tion (FFM, total body weight, and fat mass) was measured
by bioelectrical impedance analysis (BIA) (Tanita). 3T MRI to-
tal quadriceps muscle volume was assessed by the University
of Auckland Centre for Advanced Magnetic Resonance Imag-
ing. Handgrip strength (HGS) was assessed by handgrip dyna-
mometry of the dominant hand using the average of three
attempts with 1 min rest between attempts (Jammar® or
TTM Smedlays). Leg strength was measured by the use of a
customized rig attached to a load cell to determine isometric
force, with maximum voluntary contraction assessed over a
period of 10 s with considerable verbal encouragement by
the clinical exercise physiologist. Contractions were repeated
three times at 1 min intervals. Symptom burden was mea-
sured with the anorexia–cachexia scale (ACS) and physical
well-being scale (PWB) from the Functional Assessment of
Anorexia/Cancer Therapy (FAACT, Version 4). Fatigue was
measured by the Multidimensional Fatigue Symptom Inven-
tory—Short Form (MFSI-SF) and overall quality of life by
World Health Organization Quality of Life—Abbreviated
(WHOQOL-BREF). The FAACT-ACS is scored ranging from 0
to 48, and FAACT-PWB is scored ranging from 0 to 28, with
higher scores showing lower symptom burden, and the
MFSI-SF 30-item ranging from 24 to 96 with higher scores
indicating increased fatigue. Pro-inflammatory cytokine anal-
ysis (IL-1β, IL-6, and tumour necrosis factor-α) by Luminex
MAGPIX®. Both albumin and CRP levels were analysed and
then incorporated into the Glasgow prognostic score (GPS).
Compliance results were analysed as percentage attendance
of the total study sessions and percentage taken of the total
study medication. All earlier data were collected at baseline,
Weeks 3, 6, 9, 12, 16, and 20, except for MRI data at screen-
ing visit and last visit or Week 20/end of trial visit only. Study
participants were followed up for overall survival.
Treatment-emergent adverse events with an onset date on
or after the date of the first drug dose and including up to
4 weeks after last drug dose were graded by the investigator
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (Version 3.0).
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Endpoints
The primary endpoint was the acceptability of a multi-
targeted approach of supportive care in cachectic NSCLC par-
ticipants. Secondary endpoints were the change from baseline
over 20weeks in body composition by BIA, 3T MRI total quad-
riceps muscle volume, HGS and leg strength, FAACT-ACS,
FAACT-PWB, MFSI-SF, WHOQOL-BREF, pro-inflammatory cy-
tokines (IL-1β, IL-6, and tumour necrosis factor-α), albumin,
CRP and corresponding GPS, and overall survival.
Statistical analysis
Analyses of primary and secondary endpoints were based on
the full analysis set defined according to the intent-to-treat
principle. Safety analysis was performed for the safety analy-
sis population. Full analysis set consists of all participants who
were randomized with a valid post-baseline assessment. Fol-
lowing the intent-to-treat principle, participants were
analysed according to the treatment they were assigned to
at randomization. Safety analysis population consisted of all
participants who received at least one dose of any of the
study drugs/intervention. Participants were analysed accord-
ing to the treatment received. Trends in efficacy and safety of
the earlier multi-targeted approach of supportive care in ca-
chectic NSCLC participants were examined. These results will
then be used to determine the most appropriate outcome
measures to power a future study.
Results
From April 2012 until end of May 2015 (38 months), 69 pa-
tients were screened resulting in 20 patients being included,
(Figure 1 trial profile). Recruitment rate (screened vs.
consented) was 30.4% (21/69), and randomization rate of
28.9% (20/69) was due to one participant consented but died
before randomization. This rate is higher than the recently
published phase II multimodal intervention study, Pre-
MENAC27 with a recruitment rate of 11.5%, however lower
than the recruitment rates of 86% within both ROMANA 1
and 2 studies.7 Approximately a third declined to participate
31.9% (22/69), and a further third were excluded 33.3%
(23/69). The two main reasons for patients not being eligible
were decreased Eastern Cooperative Oncology Group—Per-
formance Status 8.7% (6/69) and either renal and/or cardiac
co-morbidities 5.8% (4/69). The attrition rate of those re-
cruited was 35% (7/20) at Week 6, 55% (11/20) at Week
12, and 70% (14/20) at Week 20. All participants completing
the 20 week study continued with compassionate use of
study medication and PRT sessions.
The analysis was based on 7 and 13 participants randomly
assigned to Arm A and Arm B, respectively. The baseline char-
acteristics are shown in Table 1. Groups were well matched
with respect to gender and ethnicity, with 13 male (65%), 7
female (35%), and 3 Māori (15%) participants reflecting the
current population experiencing NSCLC in New Zealand in
terms of gender and ethnicity.28 Overall, the mean and range
of baseline characteristics were similar in both groups, except
for the following: participants within Arm B entered the study
Figure 1 Trial profile for Auckland’s Cancer Cachexia evaluating Resistance Training.
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with a higher weight loss with one participant experiencing
severe weight loss greater than 15%, lower body weight,
and reduced time from diagnosis and had received a higher
number of lines of anti-cancer treatments. This suggests that
this group was experiencing progression of their advanced
cancer in a shorter time period.
Main baseline secondary outcomes for participants not
completing to Week 12 due to further disease progression
or death (n = 8/11) were compared with participants com-
pleting to Week 12 (Supporting Information, Table S1). Three
participants were well but withdrew from the study and not
included in this analysis. The results indicate that these partic-
ipants had on average lower body composition and strength
values from BIA, MRI, and HGS data and higher levels of an-
orexia/cachexia symptoms and fatigue, lower albumin levels,
and higher CRP levels resulting in a higher GPS. Acknowledg-
ing that this is a small group of data, it can be utilized to gen-
erate possible ranges for exclusion criteria for future
refractory cachexia studies.
The acceptability questionnaire was completed at a num-
ber of study time points. Results are presented at Week 12
and Week 20/end of trial visit. All participants randomized
to Arm B completed the acceptability questionnaire at either
the planned study visit or the last visit due to participant’s
preference or study team withdrawal. Unfortunately, only
three out of the seven participants randomized to Arm A
completed the questionnaire.
Acceptability and compliance data are shown in Tables 2–
4. At Week 12, only two participants in Arm A completed
the questionnaire for EPA acceptability, both scoring 5 and
one participant scoring 5 for celecoxib. In Arm B, six partici-
pants completed the questionnaire for EPA acceptability with
mean score of 3.8, and seven participants completed the
questionnaire for celecoxib with mean score of 3.7, PRT mean
score of 4.6, and EAA mean score of 3.9. At Week 20, two
participants in Arm A had EPA acceptability mean score of
4.5 and one participant again scoring 5 for celecoxib. In Arm
B, three participants completed the questionnaire for EPA ac-
ceptability all scoring 5, with all four participants scoring 5 for
celecoxib and a mean score of 4.8 for PRT and 4.5 for EAA.
Compliance (deemed as >50% for each participant) was
100% (9/9) at Week 12 and 83.3% (5/6) at Week 20 for
EPA, 88.9% (8/9) at Week 12 and 83.3% (5/6) at Week 20
for celecoxib, 100% (7/7) at Week 12 and 100% (4/4) at Week
20 for the PRT component, and 71.4% (5/7) at Week 12 and
75% (3/4) at Week 20 for EAA. One arm B participant pre-
Table 1 ACCeRT baseline characteristics
Total
n = 20
Arm A
n = 7
Arm B
n = 13
Age (years) 68.2 (42–87) 72.7 (64–81) 65.8 (42–87)
Race
European 15 (75%) 5 (33%) 10 (67%)
Māori 3 (15%) 1 (33%) 2 (67%)
Asian 1 (5%) 1 0
Filipino 1 (5%) 0 1
Gender
Male 13 (65%) 5 (38%) 8 (62%)
Female 7 (35%) 2 (29%) 5 (71%)
Body weight (kg)
All 62.9 (42.2–89.0) 64.7 (45.6–89.0) 61.9 (42.2–79.0)
Male 67.9 (45.6–89.0) 67.6 (45.6–89.0) 68.0 (49.9–79.0)
Female 53.6 (42.2–78.6) 57.6 (52.7–62.4) 52.0 (42.2–78.6)
Weight loss at entry (%) 8.0 (5.0 to 20.2) 7.1 (5.6 to 9.8) 8.4 (5.0 to 20.2)
5–10 16 (80%) 6 (38%) 10 (62%)
10–15 0 0 0
>15 1 (5%) 0 1
Low BMI 3 (15%) 1 (33%) 2 (67%)
Weight loss (days) 83 (10–296) 117 (31–296) 64 (10–115)
Time since diagnosis (days) 603 (125–1328) 723 (140–1328) 538 (125–1181)
Diagnosis NSCLC
Adenocarcinoma 14 (70%) 4 (29%) 10 (71%)
Squamous 6 (30%) 3 (50%) 3 (50%)
Albumin (g/L) 37 (25–43) 37 (34–43) 37 (25–42)
CRP (mg/L) 71 (3–322) 97 (8–322) 57 (3–164)
GPS 1.1 (0–2) 1 (0–2) 1.2 (0–2)
Lines of previous treatment
Total (excluding surgery) 2 (1–5) 1.6 (1–3) 2.2 (1–5)
Surgery 2 0 2
Targeted therapy (gefitinib/erlotinib) 11 3 8
Clinical study 4 1 3
ACCeRT, Auckland’s Cancer Cachexia evaluating Resistance Training; BMI, body mass index; CRP, C-reactive protein; GPS, Glasgow prog-
nostic score; NSCLC, non-small-cell lung cancer.
Data are mean (range) or n (%).
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study entry was experiencing intermittent diarrhoea related
to previously participating in the clinical REVEL study. Data
from this study showed toxicity (any grade) of 32% of diar-
rhoea and 16% mucosal inflammation.29 The decision was
made to stop all study medication at Week 6 and to continue
only with the PRT sessions for this arm B participant. There
was no change in the frequency of diarrhoea, and it was
never resolved and was still experienced intermittently until
the participant’s death. One arm A participant was taking
diclofenac 100 mg sustained release for bilateral hip osteoar-
thritis pre-study entry. This medication was stopped and
switched to the study medication of celecoxib 300 mg o.d.
The participant found the switch unacceptable and stopped
the celecoxib and returned to diclofenac at Week 5. Two
arm B participants found all the medication overwhelming
and had EAA dose reduction to 6 g per session (12 capsules
over the 3 days). One participant had 83 and 80% PRT
attendance at Weeks 12 and 20, respectively. This participant
was the youngest in age to be enrolled onto the study and
was the main caregiver for young children and found it diffi-
cult at times to attend for family reasons. All other partici-
pants had family members who were willing to bring them
to the twice weekly sessions. Interestingly, both participants
from Arm A scored 5 ‘strongly agree’ in wishing to commence
the PRT sessions and EAA. The earlier results conclude that
on average, the administration of EPA, celecoxib, PRT, and
EAA at this dose and frequency was acceptable in this
population.
Secondary endpoints
Weight, FFM, MRI total quadriceps muscle volume, albumin,
CRP, and GPS per trial arm are shown in Tables 5 and 6. Par-
ticipants in Arm A had a mean increase in body weight by
+0.7 kg, whereas those in Arm B lost 0.8 kg at Week 12;
however, both arms had mean weight loss of 2 and
3.7 kg, respectively, at Week 20. Figure 2A and 2B shows
percentage change in weight for each participant by trial
arm. Figure 2A depicts percentage change in total body
weight data from baseline to Week 12. Data show one net
gain and one stable value within arm A participants compared
with two net gains and one stable and four net losses within
arm B participants. This indicates the reversal and stability of
weight loss within some participants at Week 12. Figure 2B
depicts percentage change in total body weight data from
baseline to Week 20. Data show two net losses within arm
A participants compared with one net gain and three net
losses within arm B participants. This indicates the reversal
of weight loss within one arm B participant at Week 20. Total
body weight results indicate, on average, a net gain in weight
at Week 12 and then weight loss returned within Arm A. For
arm B participants completing Week 12, weight loss returned
at Week 9 onwards, while for arm B participants completing
Table 2 Acceptability questionnaire results
Arm A Arm B
Week
12
Week
20
Week
12
Week
20
EPA acceptable (5) 5 4.5 3.8 5
Celebrex acceptable (5) 5 5 3.7 5
Commencing PRT and medication
(5)
5 5
PRT acceptable (5) 4.6 4.8
EAA acceptable (5) 3.9 4.5
Continue with exercise and
medication (5)
3.9 4.5
EAA, essential amino acids; EPA, eicosapentaenoic acid; PRT, pro-
gressive resistance training.
Data are mean. The highest score available for each question is
within parentheses.
Table 3 Compliance table for individual participants by trial arm com-
pleting Week 12
Percentage taken of the total study dose per session
EPA Celecoxib PRT EAA Overall
Arm A 100 36.9a 68.5
Arm A 98.8 98.8 98.9
Mean 99.4 67.9 83.7
Arm B 100 85.7a 87.5 18.8b 73
Arm B 86.9c 86.9c 75c 69.6c 79.6
Arm B 50a 50a 91.7 54.2a 61
Arm B 100 100 100 94.6 98.7
Arm B 100 100 95.8 91.6 96.9
Arm B 78.6a 100 83 15.4b 69.3
Arm B 100 100 100 99 99.8
Mean 87.9 88.9 90.4 63.3 82.6
EAA, essential amino acids; EPA, eicosapentaenoic acid; PRT, pro-
gressive resistance training.
Twelve weeks equals 84 doses of EPA and celecoxib, 24 PRT ses-
sions, and 400 g of EAA.
aStudy medication stopped.
bPlanned dose reduction.
cStopped intermittently because of radiotherapy-induced nausea
and vomiting.
Table 4 Compliance table for individual participants by trial arm com-
pleting Week 20
Percentage taken of the total study dose per session
EPA Celecoxib PRT EAA Overall
Arm A 100 22.1a 61.1
Arm A 99.2 99.2 99.2
Mean 99.6 60.7 80.2
Arm B 100 100 100 96.4 99.1
Arm B 100 100 97.5 95 98.1
Arm B 47.1a 100 80 15.3b 60.6
Arm B 100 100 100 99.4 99.9
Mean 86.8 100 94.4 76.5 89.4
EAA, essential amino acids; EPA, eicosapentaenoic acid; PRT, pro-
gressive resistance training.
Twenty weeks equals 140 doses of EPA and celecoxib, 40 PRT ses-
sions, and 800 g of EAA.
aStudy medication stopped.
bPlanned dose reduction.
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Week 20, weight loss was delayed and returned at Week 16
onwards (Supporting Information, Figures S2 and S3).
In terms of FFM, participants in both Arm A and Arm B
gained +1.3 and +0.7 kg at Week 12, followed by FFM loss
of 1.5 and 1.7 kg, respectively, at Week 20. Figure 3A
and 3B shows percentage change in FFM for each participant
by trial arm. Figure 3A depicts percentage change in FFM
from baseline to Week 12. Data show one net gain and one
stable value within arm A participants compared with three
net gains and one stable and three net losses within arm B
participants. Figure 3B depicts percentage change in FFM
from baseline to Week 20. Data show two net loss values
within arm A participants compared with one net gain and
three net losses within arm B participants. These results indi-
cate that within Arm A, there was an increase in FFM in the
context of increasing weight at Week 12. While there was
an increase in FFM within Arm B, this occurred in the context
of stable and/or decreasing total body weight. Interestingly,
for arm B participants completing Week 20 while the total
body weight was stable, the FFM was increasing up to Week
12, which could be attributed to the addition of PRT sessions
and/or EAA and the potential stimulation of the anabolic
pathway.
Data from Table 6 show the mean MRI total quadriceps
muscle volume change from baseline to Week 20 of +12.5%
(+4.3 and +20.7%) within Arm A, compared with 3% (range
18.3 to +4.8%, n = 4) within Arm B. One arm A participant
underwent the MRI scan, but unfortunately, the images were
unable to be analysed as standardized for all the other images
due to the significant deficiency of adipose tissue. There was
no objective difference in the signal intensities between the
muscle and the surrounding tissue, resulting in an inability
Table 5 Data for main secondary outcomes for participants by trial arm
completing to Week 12
Arm A
(n = 2)
Arm B
(n = 7)
Weight (kg) Baseline 79.9 64.6
12 weeks 80.6 63.8
Difference +0.7 0.8
%
difference
+0.9 2.2
FFM (kg) Baseline 58.9 48.6
12 weeks 60.2 49.3
Difference +1.3 +0.7
%
difference
+2.3 +0.3
MRI total quadriceps muscle
volume (cm3)
Baseline
12 weeks
Difference
%
difference
Male (n = 0/n = 1) Baseline 798
12 weeks 627
Difference 171
%
difference
21.4%
Female (n = 0/n = 1) Baseline 673
12 weeks 620
Difference 53
%
difference
7.9%
Albumin (g/L) Baseline 39.0 38.4
12 weeks 35.0 35.7
Difference 4.0 2.7
%
difference
11.2 6.5
CRP (mg/L) Baseline 35.5 33.9
12 weeks 95 54.0
Difference +59.5 +20.1
%
difference
+442.7 +61.2
GPS (0–2) Baseline 0.5 1.0
12 weeks 1.5 1.1
Difference +1 +0.14
%
difference
+100 0
CRP, C-reactive protein; FFM, fat-free mass; GPS, Glasgow prognos-
tic score; MRI, magnetic resonance imaging.
Data are mean.
Table 6 Data for main secondary outcomes for participants by trial arm
completing to Week 20
Arm A
(n = 2)
Arm B
(n = 4)
Weight (kg) Baseline 79.9 69.2
20 weeks 78.0 65.6
Difference 2 3.7
%
difference
2.6 4.3
FFM (kg) Baseline 58.9 51.2
20 weeks 57.4 49.5
Difference 1.5 1.7
%
difference
2.6 2.9
MRI total quadriceps muscle
volume (cm3)
Baseline 1093 1024
20 weeks 1208 973
Difference +115 51
%
difference
+12.5 3.0
Male (n = 2/n = 2) Baseline 1093 1281
20 weeks 1208 1145
Difference +115 137
%
difference
+12.5 10.2
Female (n = 0/n = 2) Baseline 769
20 weeks 801
Difference +33
%
difference
+4.2
Albumin (g/L) Baseline 39.0 36.8
20 weeks 37.5 33.5
Difference 1.5 3.3
%
difference
3.5 7.2
CRP (mg/L) Baseline 35.5 39.0
20 weeks 65.0 97.0
Difference +29.5 +58.0
%
difference
+61.8 +128.5
GPS (0–2) Baseline 0.5 1.0
20 weeks 1.0 1.3
Difference +0.5 +0.3
%
difference
+50 +25
CRP, C-reactive protein; FFM, fat-free mass; GPS, Glasgow prognos-
tic score; MRI, magnetic resonance imaging.
Data are mean.
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to automatically segment and therefore assess the volume as
per the study protocol. An adjustment in the degree of fat
saturation at the time of acquisition may have been benefi-
cial; however, this was probably unlikely because of the
Figure 2 (A) Waterfall plot of percentage weight change for each participant by trial arm from baseline to Week 12. (B) Waterfall plot of percentage
weight change for each participant by trial arm from baseline to Week 20.
Figure 3 (A) Waterfall plot of percentage fat-free mass (FFM) change for each participant by trial arm from baseline to Week 12. (B) Waterfall plot of
percentage FFM change for each participant by trial arm from baseline to Week 20.
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deficiency of adiposity. This corresponded with BIA data of
1.1 kg of fat mass (2.5%) at the screening visit. Because of at-
trition of participants as discussed earlier, pre-treatment and
post-treatment scan data were only available for two partici-
pants allocated to Arm A and eight allocated to Arm B (two at
Week 9, data not shown). Figure 4 depicts percentage change
in MRI muscle volume from baseline to Week 20 for each par-
ticipant by trial arm. Data show two net gains within both
arm A participants compared with two net gain and two net
losses within arm B participants. These results indicate, on av-
erage, a net gain of total quadriceps muscle volume for par-
ticipants within Arm A, compared with a slight net loss
within Arm B. If taking the predefined definition of response
as per study by Greig et al.,30 individual data within Arm A
show two major responders with the net change of +4.3
and +20.7%, both over 20 weeks. Within Arm B, there was
one major and one minor responder with a net change of
+4.8 and +3.6% respectively, and two non-responders with
2 and 18.3% over 20 weeks. Both arm A participants ex-
perienced weight loss over the longest time period and were
maybe at an earlier stage in the refractory cachexia period.
However, these results suggest that the use of EPA and
celecoxib could potentially preserve muscle volume during
this early refractory cachexia stage.
Notable differences in both the albumin and CRP levels
show reduced albumin loss and lower CRP levels in Arm B
when compared with Arm A, 11.2 vs. 6.5% change in al-
bumin levels and +442.7 vs. +61.2% in CRP levels in Arms A
and B, respectively, at Week 12. This was reflected with the
corresponding GPS at Week 12 (+100 vs. +0%). One arm A
participant received antibiotics and low-dose prednisone for
a pulmonary/upper respiratory infection around Week 12,
which resulted in improved levels of albumin and CRP levels
after this study visit. The trend of CRP levels within Arm B in-
dicates that the levels of inflammation were reduced and on
average lower than Arm A until Week 12 (Supporting Infor-
mation, Figures S4 and S5), and then levels start to increase
at Week 20, and maybe attributed to the PRT sessions and
study medication allocated to Arm B. Data show that the
combination of EPA and celecoxib was not adequate in reduc-
ing or maintaining reduced CRP levels in many of the partici-
pants throughout the 20 week study. Over the 20 week
period, the mean albumin levels changed from 39 to
37.5 g/L within Arm A and 36.8 to 33.5 g/L within Arm B
and minimal change in corresponding GPS; these changes
were small over this period within a refractory cachexia pop-
ulation, suggesting a possible positive effect on inflammation
and nutrition within both study treatment arms or that the
GPS was not sensitive to identify further progression in a re-
fractory cachexia population.
Regarding the leg strength data, there were a number of
issues regarding the robustness of the equipment and the
lack of any form of calibration for potential drift over time.
Therefore, the results of the isometric leg strength testing
were taken with some trepidation and not reported. This
was further supported by lack of trend and random aberrant
results seen in the later participants who were assessed three
and four times weekly. However, it can be concluded that all
participants were happy to undergo this testing.
High adherence rates and high scores on the primary end-
point acceptable questionnaire showed that the participants
found engaging in the PRT sessions is acceptable. At each ses-
sion, participants were assessed, and the exercise pro-
gramme was adapted. It was decided to format the
reporting of the PRT sessions in terms of the planned training
programme and if the participants at each phase of the pro-
gramme under-achieved, achieved, or over-achieved as per
Table 7. This would allow the assessment of the planned pro-
gramme in terms of achievability in this population, along
with gaining data on potentially increasing the programme
in terms of sessions. Results show that all participants
achieved the planned regimen and Borg rating of perceived
exertion 11 ‘light’ at the end of Phase I/Week 4, except for
one who had a historical neck, bilateral hips, and lower spine
injury from a childhood road traffic accident; the programme
was modified to include a slower progression through the in-
tensity levels across the programme phases and under-
achieved at each phase. Table 8 shows results for Phase III/
Figure 4 Waterfall plot of percentage magnetic resonance imaging (MRI) muscle volume change for each participant by trial arm from baseline to
Week 20.
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Week 12 with three participants under-achieved, three par-
ticipants achieved, and one participant over-achieved. Results
for Phase V/Week 20 showed two participants under-
achieved and two participants achieved as per Table 9. These
results show a number of events. First, that 92% (n = 11/12)
of participants with various entry levels of fitness and weight
loss managed to achieve the planned programme within
Phase I/Week 4. Second, that the earlier low volume, low-in-
tensity training progressing to a moderate volume, moder-
ate- to high-intensity training programme was both
acceptable and safe within an NSCLC end-stage cachectic
population.
Small differences were seen within arms for the following
secondary outcomes: HGS, pro-inflammatory cytokines,
FAACT-ACS, FAACT-PWB, MFSI-SF, and WHOQOL-BREF at
both Weeks 12 and 20 (Supporting Information, Tables S2
and S3), indicating either stability or testing unable to detect
large differences within a refractory cachexia population.
The median survival within Arm A was Week 16 (n = 3/7,
43%) and Week 20 (n = 6/13, 46%) within Arm B, as shown
in Figure 5. There were 35 adverse events in all participants.
Table 10 shows treatment-related adverse events of Grades
1–2 and Grades 3 and 4 by trial arm. The most common treat-
ment-related adverse events were musculoskeletal (n = 4/7,
57%) and dyspnoea (n = 2/7, 29%) within Arm A and both in-
fection and bone pain (n = 3/13, 23%) within Arm B, all at
Grade 3. There were no exercise-related events and no treat-
ment-related deaths. There was one possible case of study
medication that induced atrial fibrillation (AF) within one
arm A participant at Week 12. The participant was asymp-
tomatic and did not require hospital admission, and it was de-
cided to continue with the study medication under regular
surveillance, as it was possible that this symptom was related
to his underlying condition of progressing NSCLC. AF is often
seen in the older population,31 and chronic pulmonary dis-
ease has also been shown to be a factor.32 Post-operative
thoracic surgery is the most frequent form of cancer-related
AF, and there has been the suggestion that the inflammatory
complication of cancer is represented by AF.32 All the earlier
factors were seen within this participant. Interestingly, 35%
(n = 7/20) of participants were already receiving a cardiac
medication at baseline.
Discussion
This study demonstrates that the two interventions assessed
in this study were both feasible and have a high acceptability
in patients with NSCLC. The multimodal intervention utilized
within Arm B was safe without any exercise-induced adverse
events. We observed that both interventions resulted in the
stabilization of total body weight and FFM loss at Week 12
(defined as ±2%), with ongoing body weight loss returning
at Week 16 and FFM loss returning at Week 20 within both
arms. However, these findings must be interpreted with cau-
tion as the trial was not powered to examine differences be-
tween arms, along with study attrition especially seen within
Arm A.
A multimodal intervention approach has been recom-
mended during many reviews, and a multimodal study similar
to the ACCeRT study has recently been published.27 Main dif-
ferences between the studies are seen in the study popula-
tion, with the ACCeRT study targeting end-stage refractory
cachexia, while the Pre-MENAC study targets the prevention
of cancer cachexia, that is, pre-cachexia/cachexia. Pre-
MENAC study is a randomized phase II feasibility trial of lung
and pancreatic cancer patients undergoing Cycles III and IV of
Table 7 Planned progression from baseline to Week 20
Phase I
Weeks 1–4
PRT 1–8
Phase II
Weeks 5–8
PRT 9–16
Phase III
Weeks 9–12
PRT 17–24
Phase IV
Weeks 13–16
PRT 25–32
Phase V
Weeks 17–20
PRT 33–40
Planned ‘Very light’ to ‘light’ Borg RPE 8–11 ‘Somewhat hard’ Borg RPE 12–13 ‘Hard’ Borg RPE 14–15
PRT, progressive resistance training; RPE, rating of perceived exertion.
Table 8 Lower and upper body Borg RPE for each individual arm B par-
ticipant completing to Week 12
Lower Upper
Baseline Week 12 Baseline Week 12
Arm B 11 11 11 11
Arm B 11 13 11 13
Arm B 11 11 11 11
Arm B 11 15 11 15
Arm B 11 13 11 13
Arm B 9 11 9 11
Arm B 11 13 11 13
Mean 10.7 12.4 10.7 12.4
RPE, rating of perceived exertion.
Table 9 Lower and upper body Borg RPE for each individual arm B par-
ticipant completing to Week 20
Lower Upper
Baseline Week 20 Baseline Week 20
Arm B 11 13 11 13
Arm B 11 15 11 15
Arm B 9 11 9 11
Arm B 11 15 11 15
Mean 10.5 13.5 10.5 13.5
RPE, rating of perceived exertion.
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standard chemotherapy, randomized to standard care or oral
nutritional supplements, anti-inflammatory (celecoxib) and
home-based aerobic (twice weekly) and resistance training
(three time weekly). Pre-MENAC study results show a mean
+0.91 kg weight gain in the treatment arm compared with a
mean 2.12 kg loss within the control arm at Week 6.27 This
was similar to Week 6 ACCeRT data (not shown) of weight
gain of +0.9 kg (Arm A) and slight loss of0.7 kg (Arm B). This
is in contrast to the results of another pre-cachexia/cachexia
population study investigating anamorelin within the
ROMANA 1 and 2 studies. Results showed a mean weight
gain +2.2 kg in the treatment arm compared with +0.14 kg
in the placebo arm (ROMANA 1) and +0.95 kg in the treat-
ment arm compared with 0.57 kg in the placebo arm
(ROMANA 2), all at 12 weeks,7 with +3.1 kg in the treatment
arm compared with +0.9 kg in the placebo arm at 24 weeks
(ROMANA 3).8
Optimum endpoint for cancer cachexia studies is currently
being investigated. At the time of designing the ACCeRT
study, change in total body weight, FFM/LBM by either BIA,
dual-energy X-ray absorptiometry (DEXA), or later lumbar-3
computed tomography analysis was just beginning, along
with measure of physical function. It was decided by the
ACCeRT study team to utilize 3T MRI total quadriceps volume
data, along with leg strength analysis to strengthen these po-
tential important endpoints. Unfortunately, as discussed ear-
lier, the leg strength data measured by isometric load cell
have been taken with some trepidation. Participants in gen-
eral complied well with the isometric leg strength testing de-
vice. This assessment was objective, and once limitations are
corrected and formalized will provide valuable data around
physical function for future studies.
ACCeRT is the first study to utilize 3T MRI data within a
cancer cachexia study and has shown that even during the re-
fractory cachexia period, it is possible to promote anabolism
with the net gain within muscle mass, as seen within both
participants within Arm A and both female participants within
Arm B, all at Week 20.
ACCeRT is also the first study to investigate the use of ex-
ercise as part of a multimodal regimen in a refractory ca-
chexia population. Interestingly, compliance for attendance
for the exercise sessions was higher than in previous pub-
lished studies in the adjuvant cancer setting. The START study
investigated exercise three times a week concurrently with
adjuvant chemotherapy for breast cancer, and results
showed the attendance rates of 72% (aerobic) and 68.2% (re-
sistance) over 18 weeks,33 compared with ACCeRT atten-
dance of 95.1% for 36 sessions/18 weeks, in this end-stage
population. Attendance rates were compared with previously
discussed Pre-MENAC study of 60% of the population attend-
ing >50% for both resistance and aerobic over 6 weeks.27
With the study design of 1:1 session with a clinical exercise
physiologist, the attendance rates are true and did not rely
on patient’s data through self-reported logs. Acceptability
as defined as a score of 4 or 5 on the questionnaire showed
that both EPA and celecoxib had the highest score, followed
by the PRT component and then EAA.
The ACCeRT study has a number of limitations. First is the
attrition rate within both arms, especially within Arm A,
which resulted in only 57% (n = 4/7) completing Week 3
and then 28.5% (n = 2/7) completing from Weeks 6 to 20.
This decreased the data gained within this study arm. Second,
the study participants all had experienced ≥5% weight loss,
and all but one had evidence of their NSCLC disease further
Figure 5 Overall survival by trial arm from study entry.
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progressing indicating refractory cachexia. Therefore, these
results are restricted to patients experiencing NSCLC and re-
fractory cachexia, and generalizability to other tumour groups
and pre-cachexia/cachexia population cannot be made. Third,
it must be acknowledged that the lack of a placebo arm and
open-label design and missing values increases the risk of bias
of these results. Future studies could possibly contain a pla-
cebo arm and where possible blinded allocation; this could
be in the form of a placebo vs. celecoxib, an isocaloric,
isonitrogenous oral supplement vs. EPA and simple gentle
stretching exercises that do not stimulate anabolic pathways
vs. PRT. Regarding possible contamination of Arm A undergo-
ing uncontrolled exercising, both participants were
questioned weekly around this. With the plethora of litera-
ture and recommended guidelines around the benefits of
physical exercise within all stages of the cancer journey,34–
36 it would be difficult to repeat this study or use a design
of a non-exercise arm in future studies. Fourth, the ACCeRT
study utilized BIA for body composition changes instead of
DEXA or lumbar-3 computed tomography data. BIA method
can underestimate the FFM compared with DEXA or com-
puted tomography analyses in oncological patients because
of fluid shifts.19 However, because the participants did not
show any signs of oedema, ascites, or dehydration, underes-
timation is likely to be a minor issue. Fifth, the expense of the
3T MRI acquisition scans and the staff to perform the analysis
is not always possible at all research/clinical centres. Sixth is
the analysis of ‘classic cachexia’ pro-inflammatory cytokines
instead of analysing the newer biomarkers, for example,
myostatin, activin A, insulin-like growth factor-1, leptin, and
zinc-alpha-2-glycoprotein, which would have determined if a
true anabolic and a reduction of the catabolic effect was
seen.
In conclusion, ACCeRT is the first study to utilize a multi-
targeted regimen in the refractory cancer population, and a
comparison with other research studies cannot be made at
this point. It has been stated that the combination of physical
inactivity, inflammation, and poor nutritional status may pre-
vent the reversal of weight and muscle loss and that any in-
tervention would be unlikely to see a reversal of the
cachexia-related symptoms within the last 90 days of life.37
The ACCeRT study results indicate that patients are willing
to be enrolled onto a multi-targeted treatment regimen and
may benefit from cachexia symptom management even dur-
ing the late/refractory stage.
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Table 10 Serious adverse events by trial arm
Arm A Arm B
Grade Grade
1–2 3 4 1–2 3 4
Cardiac
Hypotension 1 (8%)
Gastrointestinal
Dehydration
1
(14%)
Diarrhoea
1
(14%)
Obstruction
1
(8%)
Infection 1
(14%)
1
(8%)
3
(23%)
Metabolic
Hyperbilirubinaemia
1
(8%)
Hypercalcaemia 1 (8%)
Hyponatraemia 1 (8%)
Musculoskeletal
Other
4
(57%)
Neurology
Cranial CNVII 1 (8%)
Confusion
1
(14%)
1
(14%)
1
(8%)
Motor 1 (8%)
Pain
Bone
1
(14%)
3
(23%)
Tumour
1
(14%)
1
(8%)
Pulmonary/upper
respiratory
Dyspnoea
2
(29%)
1
(8%)
Pleural effusion
2
(29%)
1
(14%)
Renal
Incontinence—urinary
1
(8%)
Vascular
Thrombosis 1 (8%)
Total 4 11 1 5 12 2
Data are n (%). All treatment-emergent events displayed are de-
fined as adverse events beginning on or after first dose and
through the 28 day post-dose window.
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